By elucidating the role of circ-EGFR in modulating tumor response to cetuximab via the circ-EGFR/miR-942-3p/GAS1/Hh regulatory axis, our findings provide key molecular insights into the biologic changes associated with varying responses to anti-EGFR therapy in CRC. Here, EGFR is linked to colorectal carcinoma.